CSL and Bayer extend Helixate deal
USA-based CSL Behring, a specialist in the development of plasma-protein biotherapeutics, says it has reached an agreement with Bayer Healthcare, a subsidiary of Germany's Bayer AG, which secures the supply of Helixate recombinant factor VIII, used as a therapy for hemophilia A.
Under the terms of the extended contract, Bayer will continue to supply the product to CSL Behring, a subsidiary of Australian biopharmaceutical firm CSL, until 2017. In addition, the German firm also gained a license to certain intellectual property associated with recombinant Factor VIII as part of the settlement of outstanding litigation between the two companies. Further details of the deal were not provided.
Peter Turner, president of CSL Behring, said that "securing the long term supply of this life saving therapy is significant for the patient communities that we serve." Bayer Healthcare board member Gunnar Rieman said that the agreement would allow the company to further develop its factor VIII franchise.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze